JP7584894B2 - エキセンディン（９－３９）の緩衝製剤 - Google Patents

エキセンディン（９－３９）の緩衝製剤 Download PDF

Info

Publication number
JP7584894B2
JP7584894B2 JP2019527188A JP2019527188A JP7584894B2 JP 7584894 B2 JP7584894 B2 JP 7584894B2 JP 2019527188 A JP2019527188 A JP 2019527188A JP 2019527188 A JP2019527188 A JP 2019527188A JP 7584894 B2 JP7584894 B2 JP 7584894B2
Authority
JP
Japan
Prior art keywords
exendin
pharmaceutical formulation
liquid pharmaceutical
formulation
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019527188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535734A (ja
JP2019535734A5 (enExample
Inventor
シャオフェン・シオン
デブラ・オディンク
コリーン・エム・クレイグ
クリスティン・エム・エヌ・スミス
トレイシー・エル・マクローリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Biopharmaceuticals Inc
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of JP2019535734A publication Critical patent/JP2019535734A/ja
Publication of JP2019535734A5 publication Critical patent/JP2019535734A5/ja
Priority to JP2022123899A priority Critical patent/JP2022153624A/ja
Priority to JP2024100740A priority patent/JP2024150450A/ja
Application granted granted Critical
Publication of JP7584894B2 publication Critical patent/JP7584894B2/ja
Priority to JP2025185576A priority patent/JP2026048629A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019527188A 2016-11-21 2017-11-21 エキセンディン（９－３９）の緩衝製剤 Active JP7584894B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022123899A JP2022153624A (ja) 2016-11-21 2022-08-03 エキセンディン（９－３９）の緩衝製剤
JP2024100740A JP2024150450A (ja) 2016-11-21 2024-06-21 エキセンディン（９－３９）の緩衝製剤
JP2025185576A JP2026048629A (ja) 2016-11-21 2025-11-04 エキセンディン（９－３９）の緩衝製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662424979P 2016-11-21 2016-11-21
US62/424,979 2016-11-21
US201762517065P 2017-06-08 2017-06-08
US62/517,065 2017-06-08
PCT/US2017/062838 WO2018094404A1 (en) 2016-11-21 2017-11-21 Buffered formulations of exendin (9-39)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022123899A Division JP2022153624A (ja) 2016-11-21 2022-08-03 エキセンディン（９－３９）の緩衝製剤

Publications (3)

Publication Number Publication Date
JP2019535734A JP2019535734A (ja) 2019-12-12
JP2019535734A5 JP2019535734A5 (enExample) 2020-12-24
JP7584894B2 true JP7584894B2 (ja) 2024-11-18

Family

ID=62145888

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019527188A Active JP7584894B2 (ja) 2016-11-21 2017-11-21 エキセンディン（９－３９）の緩衝製剤
JP2022123899A Withdrawn JP2022153624A (ja) 2016-11-21 2022-08-03 エキセンディン（９－３９）の緩衝製剤
JP2024100740A Pending JP2024150450A (ja) 2016-11-21 2024-06-21 エキセンディン（９－３９）の緩衝製剤
JP2025185576A Pending JP2026048629A (ja) 2016-11-21 2025-11-04 エキセンディン（９－３９）の緩衝製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022123899A Withdrawn JP2022153624A (ja) 2016-11-21 2022-08-03 エキセンディン（９－３９）の緩衝製剤
JP2024100740A Pending JP2024150450A (ja) 2016-11-21 2024-06-21 エキセンディン（９－３９）の緩衝製剤
JP2025185576A Pending JP2026048629A (ja) 2016-11-21 2025-11-04 エキセンディン（９－３９）の緩衝製剤

Country Status (20)

Country Link
US (4) US11020484B2 (enExample)
EP (2) EP3541366B1 (enExample)
JP (4) JP7584894B2 (enExample)
CN (1) CN110267648A (enExample)
AU (3) AU2017361539B2 (enExample)
CA (1) CA3043899A1 (enExample)
CL (1) CL2019001366A1 (enExample)
DK (1) DK3541366T3 (enExample)
ES (1) ES3014024T3 (enExample)
FI (1) FI3541366T3 (enExample)
HR (1) HRP20250278T1 (enExample)
HU (1) HUE070730T2 (enExample)
IL (1) IL266568B2 (enExample)
LT (1) LT3541366T (enExample)
PL (1) PL3541366T3 (enExample)
PT (1) PT3541366T (enExample)
RS (1) RS66595B1 (enExample)
SI (1) SI3541366T1 (enExample)
SM (1) SMT202500120T1 (enExample)
WO (1) WO2018094404A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3456340T (lt) 2007-01-08 2022-05-10 The Trustees Of The University Of Pennsylvania Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
SMT202100668T1 (it) 2015-05-22 2022-01-10 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja) 2016-11-21 2024-11-18 アイガー・バイオファーマシューティカルズ・インコーポレイテッド エキセンディン（９－３９）の緩衝製剤
ES2894629T3 (es) 2017-06-16 2022-02-15 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CA3115527A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
MX2022014090A (es) 2020-05-12 2023-02-27 Regeneron Pharma Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
US20240307501A1 (en) 2021-06-21 2024-09-19 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
WO2023229987A1 (en) * 2022-05-25 2023-11-30 Neuvian LLC Vaginal care compositions comprising exosomes and its uses for improving vaginal health
CN116606367A (zh) * 2022-05-31 2023-08-18 南京盛德瑞尔医药科技有限公司 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物
WO2024220962A1 (en) * 2023-04-21 2024-10-24 The Board Of Trustees Of The Leland Stanford Junior University Glp-1r antagonism to improve nutrition following gastrointestinal surgery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534450A (ja) 1999-01-14 2002-10-15 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト製剤とその投与方法
US20080269130A1 (en) 2007-01-08 2008-10-30 Doris Stoffers Methods and compositions for treating hypoglycemic disorders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK155694A3 (en) 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
CZ297361B6 (cs) 1998-01-30 2006-11-15 Novo Nordisk A/S Injekcní stríkacka
ES2233089T3 (es) 1998-12-10 2005-06-01 Agouron Pharmaceuticals, Inc. Antagonistas no peptidos del receptor de glp-1 y metodos de uso.
EP1658856B1 (en) 1999-01-14 2010-03-17 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PL2409707T3 (pl) 2004-04-15 2015-08-31 Amylin Pharmaceuticals Llc Urządzenie o przedłużonym uwalnianiu na bazie polimeru
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
LT2347762T (lt) 2005-08-19 2019-08-26 Amylin Pharmaceuticals, Llc Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
GEP20125628B (en) * 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
AU2007267833B2 (en) * 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
ES2399651T3 (es) 2008-07-08 2013-04-02 Novartis Ag Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
SMT202000405T1 (it) 2008-09-04 2020-09-10 Amylin Pharmaceuticals Llc Formulazioni a rilascio prolungato usando veicolanti non acquosi
EP2413952B2 (en) 2009-04-03 2019-10-02 Société des Produits Nestlé S.A. Improvement in promotion of healthy catch-up growth
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
SMT202100668T1 (it) 2015-05-22 2022-01-10 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja) * 2016-11-21 2024-11-18 アイガー・バイオファーマシューティカルズ・インコーポレイテッド エキセンディン（９－３９）の緩衝製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534450A (ja) 1999-01-14 2002-10-15 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト製剤とその投与方法
US20080269130A1 (en) 2007-01-08 2008-10-30 Doris Stoffers Methods and compositions for treating hypoglycemic disorders

Also Published As

Publication number Publication date
HRP20250278T1 (hr) 2025-04-25
EP3541366A1 (en) 2019-09-25
DK3541366T3 (da) 2025-03-03
HUE070730T2 (hu) 2025-06-28
FI3541366T3 (fi) 2025-03-06
WO2018094404A1 (en) 2018-05-24
US11738086B2 (en) 2023-08-29
EP3541366A4 (en) 2020-08-05
PL3541366T3 (pl) 2025-04-28
US11020484B2 (en) 2021-06-01
RS66595B1 (sr) 2025-04-30
EP3541366B1 (en) 2024-12-25
AU2017361539A1 (en) 2019-07-04
JP2026048629A (ja) 2026-03-17
AU2017361539B2 (en) 2023-06-29
US20260034221A1 (en) 2026-02-05
AU2023237119B2 (en) 2025-04-10
PT3541366T (pt) 2025-03-14
US20210315995A1 (en) 2021-10-14
SI3541366T1 (sl) 2025-05-30
CA3043899A1 (en) 2018-05-24
LT3541366T (lt) 2025-03-10
IL266568B1 (en) 2024-05-01
JP2019535734A (ja) 2019-12-12
CN110267648A (zh) 2019-09-20
BR112019010236A2 (pt) 2019-08-20
IL266568B2 (en) 2024-09-01
JP2022153624A (ja) 2022-10-12
SMT202500120T1 (it) 2025-05-12
IL266568A (en) 2019-07-31
JP2024150450A (ja) 2024-10-23
ES3014024T3 (en) 2025-04-16
AU2025205195A1 (en) 2025-07-24
US20240042035A1 (en) 2024-02-08
CL2019001366A1 (es) 2019-11-08
AU2023237119A1 (en) 2023-10-19
US20200069802A1 (en) 2020-03-05
EP4591853A1 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
US12220444B2 (en) Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
JP2019535734A5 (enExample)
US20140148384A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK40014636A (en) Buffered formulations of exendin (9-39)
HK40014636B (en) Buffered formulations of exendin (9-39)
BR112019010236B1 (pt) Formulações tamponadas de exendina (9-39) e uso das mesmas
BR122025006444A2 (pt) Formulações tamponadas de exendina (9-39)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220803

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220812

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220816

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220902

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241106

R150 Certificate of patent or registration of utility model

Ref document number: 7584894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350